<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01195246</url>
  </required_header>
  <id_info>
    <org_study_id>DV2-HBV-18</org_study_id>
    <secondary_id>2010-019633-10</secondary_id>
    <nct_id>NCT01195246</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis</brief_title>
  <official_title>An Open-Label, Randomized, Multi-Center Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Engerix-B® and Fendrix® in Adults on Hemodialysis Who Have Previously Received Hepatitis B Vaccination and Are Not Seroprotected</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dynavax Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dynavax Technologies Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the immune response to HEPLISAV™ booster injection
      with the immune response to Engerix-B® and Fendrix® booster vaccinations among patients with
      end stage renal disease (ESRD) on hemodialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The immune response of HEPLISAV compared with Engerix-B and Fendrix and measured by
      seroprotection rate (SPR) at 4 weeks after the booster injection
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with seroprotection rate (SPR), defined as the percentage of subjects with anti-HBsAg serum concentration of 10 milli-international unit (mIU)/mL or higher, measured at Week 4</measure>
    <time_frame>week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall incidence of post-injection reactions and adverse events in each treatment group</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>HEPLISAV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL HEPLISAV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Engerix-B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.0 mL Engerix-B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fendrix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 mL Fendrix</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HEPLISAV</intervention_name>
    <description>Intramuscular (IM) injection on Day1</description>
    <arm_group_label>HEPLISAV</arm_group_label>
    <other_name>Hepatitis B Vaccine (Recombinant), Adjuvanted</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix-B</intervention_name>
    <description>Intramuscular (IM) injection on Day 1</description>
    <arm_group_label>Engerix-B</arm_group_label>
    <other_name>Hepatitis B Vaccine (Recombinant)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fendrix</intervention_name>
    <description>Intramuscular (IM) injection on Day 1</description>
    <arm_group_label>Fendrix</arm_group_label>
    <other_name>Hepatitis B Vaccine (Recombinant)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age

          -  Has loss of renal function and is receiving hemodialysis treatments

          -  Is not seroprotected against hepatitis B (has anti-HBs &lt; 10 mIU/mL)

          -  In the opinion of the investigator, is clinically stable

          -  Be serum negative for HBsAg, anti-hepatitis B core antigen (HBc), hepatitis C virus
             (HCV), and HIV

          -  Is not scheduled to undergo a kidney transplant during the study period

          -  If female, and of childbearing potential, subject must be: surgically sterile or
             neither pregnant nor breast-feeding, consistently using a highly effective method of
             birth control for at least one month prior to study entry, and agrees to use two forms
             of birth control consistently throughout the study.

        Exclusion Criteria:

          -  If female, is pregnant, breastfeeding, or planning a pregnancy;

          -  Has a history of or is at high risk for recent exposure to HBV, HCV, or HIV;

          -  Has known history of autoimmune disease;

          -  Has history of sensitivity to any component of study vaccines;

          -  Has a current condition other than renal disease or has substance or alcohol abuse
             that would interfere with compliance or with interpretation of the study results;

          -  Is undergoing chemotherapy or expected to receive chemotherapy during the study
             period; has a diagnosis of cancer within the last 5 years other than squamous or basal
             cell carcinoma of the skin;

          -  Has uncontrolled diabetes;

          -  Has received a kidney transplant previously that is still functioning and requires
             anti-rejection medication;

          -  Has received any blood products or immunoglobulin within 3 months prior to study
             entry, or likely to require infusion of blood products during the study period;

          -  Has received the following prior to the study injection: 3 days: intravenous iron; 21
             days: any inactivated virus or bacterial vaccine; 28 days: any live virus or bacterial
             vaccine; systemic corticosteroids (more than 3 consecutive days) or other
             immunomodulators or immune suppressive medication, with the exception of inhaled
             steroids; granulocyte colony stimulating factor (G-CSF) or granulocyte-macrophage
             colony stimulating factor (GM-CSF); any other investigational medicinal agent;

          -  At any time: an injection of deoxyribonucleic acid (DNA) plasmids or oligonucleotides;
             investigational or intradermal hepatitis B vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madgeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim-Kafertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oberschleißheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Velbert</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.dynavax.com</url>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2010</study_first_submitted>
  <study_first_submitted_qc>September 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2010</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>end stage renal failure</keyword>
  <keyword>renal failure</keyword>
  <keyword>kidney failure</keyword>
  <keyword>kidney failure, chronic</keyword>
  <keyword>chronic kidney failure</keyword>
  <keyword>hepatitis B virus (HBV) vaccine</keyword>
  <keyword>hepatitis B vaccine</keyword>
  <keyword>hepatitis B</keyword>
  <keyword>hepatitis</keyword>
  <keyword>HBV</keyword>
  <keyword>prevention and control</keyword>
  <keyword>dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>a/o August 2016, decision is still pending.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

